Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics (Nasdaq: AKBA) granted a stock option inducement award to one newly hired employee on August 31, 2026.

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) granted a stock option inducement award to one newly hired employee on August 31, 2026. The option covers an aggregate of 8,400 shares of Akebia common stock at an exercise price of $0.92 per share, equal to the closing price on the grant date. The award was approved under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter, subject to continued service, and have a 10-year term under Akebia’s inducement award program and stock option agreement.

Argus Sep 2 session 10 alerts

+3.77% close to close 3.7x rel. volume Open Argus

Details

Market reaction after inducement option grant: AKBA +3.77% in the Sep 2 session

+9.2% Peak in 20 hr 26 min

$279.88M Market Cap

In the Sep 2 session, AKBA gained 3.77%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.2% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 3.7x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Recent insider data recorded Net Selling of 56,019 shares. That platform context adds an ownership s...

Analysis

Recent insider data recorded Net Selling of 56,019 shares. That platform context adds an ownership signal to this routine grant disclosure, while the four-year vesting schedule and continued-service condition remain the principal terms to monitor.

Key Figures

Shares Granted: 8,400 shares Exercise Price: $0.92 per share Vesting Period: 4 years +3 more

Shares Granted

8,400 shares

One newly hired employee; August 31, 2026 grant

Exercise Price

$0.92 per share

Equal to the closing price on the grant date

Vesting Period

4 years

Subject to continued employee service

First Vesting Tranche

25%

Vests on the first anniversary of the grant date

Remaining Vesting Tranche

75%

Vests quarterly after the first anniversary

Option Term

10-year term

Subject to the inducement award program and option agreement

Historical Context

5 past events · Latest: Aug 05

5 events

1. Aug 05

   earnings report

   24h Move

   -26.0%

   Revenue declined and the company reported a net loss amid generic competition.

2. Aug 03

   inducement grants

   24h Move

   +0.8%

   Options covering 61,000 shares were granted to two newly hired employees.

3. Aug 03

   Phase 2 trial

   24h Move

   -0.8%

   Akebia initiated a Phase 2 basket trial of ebribafusp in rare kidney diseases.

4. Jul 29

   earnings scheduling

   24h Move

   -0.8%

   The company scheduled release of second-quarter 2026 financial results.

5. Jul 02

   inducement grants

   24h Move

   +4.8%

   Options covering 125,600 shares were granted to three new employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on August 31, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $0.92 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco
mcarrasco@akebia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Akebia Therapeutics (AKBA) grant on August 31, 2026?

Akebia granted a stock option covering 8,400 shares of its common stock to one newly hired employee. According to Akebia, the options were issued as an inducement award under its program and Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new Akebia Therapeutics (AKBA) inducement stock options?

The exercise price of the inducement stock options is $0.92 per share. According to Akebia, this price equals the closing price of its common stock on the August 31, 2026 grant date.

How do the Akebia Therapeutics (AKBA) inducement stock options vest for the new employee?

The inducement stock options vest over four years. According to Akebia, 25% of the shares vest on the first anniversary of the grant date, with the remaining 75% vesting quarterly thereafter, subject to continued service.

What is the term of the Akebia Therapeutics (AKBA) inducement stock options granted in 2026?

Each inducement stock option has a 10-year term. According to Akebia, the options are subject to the company’s inducement award program and a stock option agreement that governs the specific terms and conditions.

Why did Akebia Therapeutics (AKBA) use Nasdaq Listing Rule 5635(c)(4) for this stock option grant?

Akebia used Nasdaq Listing Rule 5635(c)(4) because the grant is a material inducement to the employee entering into employment. According to Akebia, this rule allows equity awards outside stockholder-approved plans for such hiring incentives.

How many Akebia Therapeutics (AKBA) shares are covered by the 2026 inducement award?

The 2026 inducement award covers options to purchase 8,400 shares of Akebia common stock. According to Akebia, these shares are subject to vesting over four years and a 10-year option term.